Related Experiment Video
Updated: Dec 27, 2025
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
HMGA2 Polymorphisms and Hepatoblastoma Susceptibility: A Five-Center Case-Control Study
Li Li1, Zhenjian Zhuo2, Zhen Yang1,3
1Kunming Key Laboratory of Children's Infection and Immunity, Yunnan Key Laboratory of Children's Major Disease Research, Yunnan Institute of Pediatrics Research, Kunming Children's Hospital, Kunming, Yunnan, 650228, People's Republic of China.
This study investigated High Mobility Group A2 (HMGA2) single nucleotide polymorphisms (SNPs) and their association with hepatoblastoma risk. Certain HMGA2 SNPs showed a weak influence on hepatoblastoma susceptibility, particularly in males and early-stage cases.
Area of Science:
- Genetics and Epidemiology
- Oncology
- Molecular Biology
Background:
- Hepatoblastoma is a rare pediatric liver cancer with an unknown etiology.
- No prior epidemiological studies have examined the link between High Mobility Group A2 (HMGA2) single nucleotide polymorphisms (SNPs) and hepatoblastoma risk.
- This study pioneers the investigation into whether specific HMGA2 SNPs impact hepatoblastoma susceptibility.
Purpose of the Study:
- To explore the association between three specific High Mobility Group A2 (HMGA2) single nucleotide polymorphisms (SNPs) – rs6581658, rs8756, and rs968697 – and the risk of developing hepatoblastoma.
- To determine if these HMGA2 SNPs contribute to hepatoblastoma susceptibility in a Chinese population.
Main Methods:
- A case-control study was conducted with 275 hepatoblastoma cases and 1018 controls from five Chinese hospitals.
- Genotyping of HMGA2 SNPs (rs6581658, rs8756, rs968697) was performed using the PCR-based TaqMan method.
- Risk estimates were calculated using odds ratios (ORs) and 95% confidence intervals (CIs).
Main Results:
- The rs968697 T>C polymorphism was significantly associated with reduced hepatoblastoma risk in the additive model (adjusted OR=0.73).
- Individuals with 2-3 favorable genotypes exhibited significantly lower hepatoblastoma risk compared to those with 0-1 favorable genotypes (adjusted OR=0.71).
- Stratification analysis indicated that rs968697 TC/CC genotypes and the presence of 2-3 protective genotypes were linked to decreased risk in males, clinical stage I+II cases, and children aged 17 months or older.
Conclusions:
- The study suggests that High Mobility Group A2 (HMGA2) gene single nucleotide polymorphisms (SNPs) have a weak influence on hepatoblastoma susceptibility.
- The findings highlight a potential protective role of certain HMGA2 SNP combinations, particularly in specific demographic and clinical subgroups.
- Further validation with larger, multi-ethnic cohorts is recommended to confirm these preliminary results.
